Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC)

Autor:	Awada, A. H., Zematis, M., Ochsenreither, S., Eefsen, R. L., Arnold, D., Cicenas, S., Yachnin, J., Pfeiffer, P., Paz-Ares, L., Jungels, C., Greil, R., Poulsen, L. Østergaard, Van Cutsem, E., Ribas, I. Garcia, Thorsson, L., Collignon, J. J.
Jazyk:	angličtina
Rok vydání:	2021
Zdroj:	Awada, A H, Zematis, M, Ochsenreither, S, Eefsen, R L, Arnold, D, Cicenas, S, Yachnin, J, Pfeiffer, P, Paz-Ares, L, Jungels, C, Greil, R, Poulsen, L O, Van Cutsem, E, Ribas, I G, Thorsson, L & Collignon, J J 2021, ' Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC) ', Annals of Oncology, vol. 32, no. Suppl. 5, pp. S602-S603 . https://doi.org/10.1016/j.annonc.2021.08.1060 Awada, A H, Zematis, M, Ochsenreither, S, Eefsen, R L, Arnold, D, Cicenas, S, Yachnin, J, Pfeiffer, P, Paz-Ares, L, Jungels, C, Greil, R, Poulsen, L Ø, Van Cutsem, E, Ribas, I G, Thorsson, L & Collignon, J J 2021, ' Nadunolimab (CAN04), a first-in-class monoclonal antibody against IL1RAP, in combination with chemotherapy in subjects with pancreatic cancer (PDAC) and non-small cell lung cancer (NSCLC) ', Annals of Oncology, vol. 32, no. Suppl. 5, pp. S602-S603 . https://doi.org/10.1016/j.annonc.2021.08.1060
DOI:	10.1016/j.annonc.2021.08.1060
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::9721ee19ea3fa3ee6baf59f099d706e1 https://portal.findresearcher.sdu.dk/da/publications/846e5c54-8ec7-4e04-a21b-31b452feec96 Zobrazit plný text záznamu